Pacira Pharmaceuticals (NASDAQ:PCRX) Given a $55.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $55.00 price target on Pacira Pharmaceuticals (NASDAQ:PCRX) in a report released on Thursday, January 4th. The brokerage currently has a buy rating on the stock.

PCRX has been the subject of several other research reports. UBS Group initiated coverage on shares of Pacira Pharmaceuticals in a research note on Wednesday, September 6th. They issued a market perform rating for the company. Oppenheimer initiated coverage on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. They issued a market perform rating for the company. CIBC initiated coverage on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. They issued a market perform rating for the company. Jefferies Group reiterated a buy rating and issued a $59.00 price objective on shares of Pacira Pharmaceuticals in a research note on Thursday, September 7th. Finally, Mizuho restated a buy rating and issued a $53.00 target price on shares of Pacira Pharmaceuticals in a research report on Monday, September 25th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the company’s stock. Pacira Pharmaceuticals currently has a consensus rating of Hold and an average price target of $49.00.

Shares of Pacira Pharmaceuticals (PCRX) traded down $1.25 on Thursday, hitting $41.50. 1,651,800 shares of the stock were exchanged, compared to its average volume of 1,027,171. The company has a current ratio of 6.99, a quick ratio of 6.24 and a debt-to-equity ratio of 1.03. The company has a market cap of $1,710.00, a P/E ratio of -31.68 and a beta of 2.20. Pacira Pharmaceuticals has a 52 week low of $29.81 and a 52 week high of $58.95.

Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.15. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $68.99 million. Pacira Pharmaceuticals had a negative net margin of 18.25% and a negative return on equity of 13.77%. Pacira Pharmaceuticals’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.20 EPS. analysts expect that Pacira Pharmaceuticals will post -0.85 earnings per share for the current year.

In other news, CAO Kristen Marie Williams sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $40.00, for a total value of $400,000.00. Following the transaction, the chief accounting officer now owns 23,455 shares in the company, valued at approximately $938,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP James B. Jones sold 850 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $41.11, for a total transaction of $34,943.50. The disclosure for this sale can be found here. Insiders have sold a total of 70,075 shares of company stock worth $2,707,452 over the last three months. Insiders own 6.60% of the company’s stock.

Several hedge funds and other institutional investors have recently modified their holdings of PCRX. BlackRock Inc. lifted its position in shares of Pacira Pharmaceuticals by 9.2% during the 2nd quarter. BlackRock Inc. now owns 3,478,281 shares of the company’s stock valued at $165,914,000 after acquiring an additional 294,494 shares during the period. Vanguard Group Inc. lifted its position in shares of Pacira Pharmaceuticals by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 3,072,074 shares of the company’s stock valued at $146,538,000 after acquiring an additional 211,982 shares during the period. HealthCor Management L.P. lifted its position in shares of Pacira Pharmaceuticals by 63.1% during the 2nd quarter. HealthCor Management L.P. now owns 1,793,799 shares of the company’s stock valued at $85,564,000 after acquiring an additional 693,799 shares during the period. Westfield Capital Management Co. LP lifted its position in shares of Pacira Pharmaceuticals by 5.3% during the 3rd quarter. Westfield Capital Management Co. LP now owns 1,285,850 shares of the company’s stock valued at $48,284,000 after acquiring an additional 64,510 shares during the period. Finally, Macquarie Group Ltd. lifted its position in shares of Pacira Pharmaceuticals by 5.8% during the 3rd quarter. Macquarie Group Ltd. now owns 1,154,545 shares of the company’s stock valued at $43,353,000 after acquiring an additional 63,015 shares during the period.

COPYRIGHT VIOLATION WARNING: “Pacira Pharmaceuticals (NASDAQ:PCRX) Given a $55.00 Price Target by HC Wainwright Analysts” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/hc-wainwright-analysts-give-pacira-pharmaceuticals-pcrx-a-55-00-price-target.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Analyst Recommendations for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply